Table 1 Clinical outcomes of patients in the two groups.
|  | Low dose ATG/PTCy regimen (n = 31) | Standard-dose ATG regimen (n = 36) | P |
|---|---|---|---|
CI of grades I–IV aGvHD at 180 days | 49.7% | 79.3% | 0.065 |
CI of grades II–IV aGvHD at 180 days | 17.0% | 40.2% | 0.042 |
CI of grades III–IV aGvHD at 180 days | 3.2% | 23.1% | 0.025 |
CI of cGVHD at 1 year | 42.7% | 57.7% | 0.190 |
CI of moderate to severe cGVHD at 1 year | 11.2% | 40.1% | 0.029 |
Viral infection | |||
CMV viremia | 13 (41.9%) | 23 (63.8%) | 0.072 |
  CMV disease | 5 (16.1%) | 5 (13.9%) | 1.000 |
  EB viremia | 14 (45.2%) | 24 (66.7%) | 0.076 |
PTLD EBV related | 0 (0.0%) | 1 (2.8%) | 1.000 |
CIR at 1 year | 22.9% | 8.7% | 0.042 |
NRM at 1 year | 12.9% | 36.2% | 0.038 |
Causes of NRM | |||
 GvHD | 0 (0%) | 7 (23.3%) | 0.028 |
 Infection | 0 (0%) | 5 (13.9%) | 0.091 |
 MOF | 1 (3.2%) | 1 (2.8%) | 1.000 |
 Graft failure/dysfunction | 3 (9.7%) | 1 (2.8%) | 0.502 |
Early mortality (Within 3 months post transplant) | 3 (9.7%) | 11 (30.6%) | 0.036 |
OS (1 year) | 74.9% | 59.4% | 0.255 |
LFS (1 year) | 64.2% | 55.0% | 0.400 |
